Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

Introduction Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients with multiple sclerosis (MS) are reported to exhibit greater disease severity. Geographical location and genetics play a role in differences observed across Hispanic/Latino subpopulations. We evaluated real-w...

Full description

Saved in:
Bibliographic Details
Published in:Neurology and therapy 2020-12, Vol.9 (2), p.495-504
Main Authors: Chinea, Angel, Amezcua, Lilyana, Vargas, Wendy, Okai, Annette, Williams, Mitzi J., Su, Ray, Parks, Becky, Mendoza, Jason P., Lewin, James B., Jones, Cynthia C.
Format: Article
Language:English
Subjects:
Dimethyl fumarate
Internal Medicine
Medicine
Medicine & Public Health
Multiple sclerosis
Neurology
Original Research
Safety and effectiveness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients with multiple sclerosis (MS) are reported to exhibit greater disease severity. Geographical location and genetics play a role in differences observed across Hispanic/Latino subpopulations. We evaluated real-world safety and effectiveness of dimethyl fumarate (DMF) on MS disease activity in Hispanic/Latino patients. Methods ESTEEM is an ongoing, 5-year, multinational, prospective study evaluating long-term safety and effectiveness of DMF in patients with MS. This interim analysis included patients newly prescribed DMF in routine practice at 394 sites globally. Results Overall, 4986 non-Hispanic/non-Latino and 98 Hispanic/Latino patients were analyzed; median (range) follow-up was 18 (2–37) months. Unadjusted annualized relapse rates (ARRs) for 12 months before DMF initiation versus 36 months post DMF initiation, respectively, were: non-Hispanic/non-Latino patients, 0.82 (95% CI 0.80–0.84) versus 0.10 (95% CI 0.09–0.10), 88% lower ARR ( P  
ISSN:2193-8253
2193-6536
DOI:10.1007/s40120-020-00192-6